Video

Associating Genes With Melanoma Risk

Author(s):

Maria T. Landi, M.D., Ph.D.
Conference|World Congress on Melanoma

Maria T. Landi, M.D., Ph.D., principal investigator at the National Cancer Institute (NCI) and National Institutes of Health (NIH) discusses a recent study that identified genetic variations that may be linked with increased melanoma risk.

Maria T. Landi, M.D., Ph.D., principal investigator at the National Cancer Institute (NCI) and National Institutes of Health (NIH) discusses a recent study that identified genetic variations that may be linked with increased melanoma risk.

The large, meta-analysis observed 27,000 patients with melanoma and 50,000 controls from the United States, Australia and Europe and discovered 19 additional genes that showed a strong correlation with melanoma risk. Included were alterations in pigmentation pathways, telomeres, immunity and signalisn and transcription pathways.

In the future, Landi and her research team will be adding about 10,000 more patients to hopefully identify more genetic associations with melanoma.

Related Videos
Image of man with grey hair.
Image of woman with black hair.
Image of woman with blonde hair.
Image of a man in a suit.
Image of woman with brown hair.
Image of a man with short black hair.
Image of a woman with wavy blonde hair wearing glasses.
Image of man with black hair.
Image of a woman with layered hair, wearing a bright blue cardigan.
Related Content
Image of woman holding a pink ribbon.
December 20th 2024

Low ctDNA Levels May Show Longer Recurrence-Free Interval in Breast Cancer

Spencer Feldman
In patients with triple-negative breast cancer, ctDNA was most commonly identified within six months after treatment, reflecting the disease’s typical pattern of early recurrence.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of red blood cells.
December 18th 2024

Imbruvica-Venetoclax Shows Promise in Managing CLL

Spencer Feldman
A combination of Imbruvica and venetoclax showed significantly prolonged progression-free survival in patients with untreated CLL, an expert explained.
Top Cancer Headlines from 2023
January 2nd 2024

Top Cancer Headlines from 2023

Alex Biese Brielle Benyon
From Jimmy Buffett's death to the chemo shortage and cannabis use in cancer care, here is a look back at some of our most popular oncology stories from 2023.
Image of Dr. Brandon Blue.
December 17th 2024

Black Patients With Myeloma Face Taste, Skin Side Effects from Talvey

Alex Biese
Black patients may be more affected by certain side effects from Talvey compared with White patients with multiple myeloma, an expert told CURE®.
Illustration of cross hairs on cancer in the blood.
December 16th 2024

Tecartus After Outpatient Lymphodepletion Safe, Effective in B-ALL and MCL

Chris Ryan
Outpatient lymphodepletion followed by Tecartus was found to be safe and effective in treating B-cell acute lymphoblastic leukemia and mantle cell lymphoma.